Arthrosi Therapeutics Forges Ahead with a New Generation of Gout Treatment in Phase 2 Trials

LAGUNA HILLS, Calif. - Sept. 3, 2019 - PRLog -- Arthrosi Therapeutics, a clinical-stage biopharmaceutical company focused on developing a best-in-class treatment for gout, is in the midst of their Phase 2a clinical trial.  Two clinical studies conducted in Australia for their lead asset, AR882, demonstrated a strong safety profile and pharmacodynamics outcome in healthy volunteers following single or multiple dosing of AR882.  The results indicate AR882 considerably outperforms the current frontline therapies for gout and has the potential to provide clinical benefit in hyperuricemia and gout patients.  Arthrosi expects to submit their US IND at the end of this year and a Chinese IND in early 2020.

"Gout has a huge market. In China, there are 200 million hyperuricemia patients and nearly 20 million gout patients while the United States has 120 million hyperuricemia patients and 12 million gout patients," said Litain Yeh, Arthrosi's CEO," At Arthrosi, we are committed to the independent development of new drugs to treat gout related symptoms.  Eventually, Arthrosi's treatment will become the first-line medication for gout treatment."

Arthrosi's management has started their B1 round of fundraising to facilitate the next stage of clinical trials.

Viva BioInnovator is proud to be an early investor in Arthrosi Therapeutics and continues to support their ongoing efforts to advance AR882 as the next generation of gout treatment.

"We have been a supporter of Arthrosi since the very beginning and are pleased to see how far they have progressed. We see it as validation of our internal model when a company we both incubated and invested in has obtained good results in the clinic." said Cheney Mao, CEO of Viva Biotech, "Viva is fortunate to be a partner and investor as they move forward on the path to approval."

About Arthrosi

Arthrosi is a clinical-stage biopharmaceutical company based in California. They are working on an oral, best-in-class treatment for gout with a second pipeline in oncology.  They can leverage extensive previous expertise to develop a novel therapy with early validation to help millions of patients suffering from this painful condition.

Contact:

Dr. Shunqi Yan, COO

shunqi.yan@arthrosi.com

About Viva BioInnovator

As the investment division of Viva Biotech, Viva BioInnovator has incubated over 30 startup biotech companies and plans to work with 100 more in the next two years. By working with its leading structure-based and integrated drug discovery platform, Viva operates a full spectrum of early-stage drug discovery technologies from hit identification to clinical candidate nomination, all combined with a unique equity-for-service model alongside traditional early-stage investment.

Contact:

Chloe Kamps

Chloe.kamps@vivabiotech.com

www.vivabioinnovator.com